Free Trial

This company has been marked as potentially delisted and may not be actively trading.

IMARA (IMRA) Competitors

IMARA logo

IMRA vs. MOR, GMTX, CALT, ZYME, CMRX, CDMO, MENS, SBTX, MBX, and RVNC

Should you be buying IMARA stock or one of its competitors? The main competitors of IMARA include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), and Revance Therapeutics (RVNC).

IMARA vs. Its Competitors

IMARA (NASDAQ:IMRA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

In the previous week, IMARA had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for IMARA and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat IMARA's score of 0.00 indicating that MorphoSys is being referred to more favorably in the news media.

Company Overall Sentiment
IMARA Neutral
MorphoSys Neutral

IMARA has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMARAN/AN/A$1.49M$0.051,027.00
MorphoSys$238.28M11.99-$205.35M-$3.48-5.45

IMARA has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. IMARA's return on equity of 2.12% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
IMARAN/A 2.12% 2.00%
MorphoSys -226.79%-694.31%-22.55%

IMARA has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

49.3% of IMARA shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 37.3% of IMARA shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

IMARA beats MorphoSys on 9 of the 12 factors compared between the two stocks.

Get IMARA News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMRA vs. The Competition

MetricIMARAPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.35B$838.34M$5.56B$9.10B
Dividend YieldN/A4.84%5.06%4.02%
P/E Ratio1,027.211.3828.2620.26
Price / SalesN/A241.37404.92152.16
Price / Cash75.2417.6937.1257.67
Price / Book14.936.588.045.49
Net Income$1.49M-$23.83M$3.19B$250.45M

IMARA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMRA
IMARA
N/A$51.35
-0.4%
N/AN/A$1.35BN/A1,027.2141Insider Trade
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
GMTX
Gemini Therapeutics
N/A$52.96
-2.8%
N/A+21.3%$2.29BN/A-52.9630
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
ZYME
Zymeworks
2.9179 of 5 stars
$12.41
-1.1%
$21.00
+69.2%
+32.5%$863.45M$93.38M-8.27460
CMRX
Chimerix
0.5456 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6146 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+50.2%$799.18M$139.91M-5.23320News Coverage
High Trading Volume
MENS
Jyong Biotech
N/A$8.48
-0.2%
N/AN/A$646.23MN/A0.0031Positive News
Gap Up
SBTX
Silverback Therapeutics
N/A$17.45
-4.1%
N/A+55.9%$629.21MN/A-7.2183High Trading Volume
MBX
MBX Biosciences
1.7077 of 5 stars
$11.61
+1.8%
$37.50
+223.0%
N/A$388.05MN/A0.0036
RVNC
Revance Therapeutics
2.6351 of 5 stars
$3.65
flat
$8.45
+131.5%
N/A$381.02M$234.04M-1.89500

Related Companies and Tools


This page (NASDAQ:IMRA) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners